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Abstract Novel peptides homing to angiogenic vessels were
recently isolated from a phage-displayed random pentadecapep-
tide library. One of the isolated peptides, ASSSYPLIHWRP-
WAR, significantly suppressed the migration of VEGF-
stimulated human umbilical vein endothelial cells. Dendoric
ASSSYPLIHWRPWAR-peptide suppressed the formation of
new blood vessels in dorsal air sac model mice. Furthermore,
ASSSYPLIHWRPWAR-peptide and the fragment peptides
containing WRP, which is revealed to be an epitope sequence,
significantly suppressed the tumor growth, although 15-mer
shuffled peptide derived from ASSSYPLIHWRPWAR and
pentapeptides with alanine substitution of each residue of WRP
did not. Taken together, ASSSYPLIHWRPWAR-peptide may
cause tumor dormancy through inhibition of angiogenesis, and
the WRP sequence may be the minimal and essential sequence
for this activity. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Antiangiogenic agents induce tumor dormancy, suppress
metastases, and essentially cause little side e¡ects [1,2]. There-
fore, many antiangiogenic agents have been developed one
after another, and preclinical and clinical studies are now in
progress. The angiogenic vasculature would not be expected
to acquire drug-resistance. In fact, antiangiogenic-scheduled
chemotherapy combined with an angiogenesis inhibitor eradi-
cated even the drug-resistant tumor cells [3]. On the other
hand, vascular targeting has become a focus of interest, since
certain drugs or drug carriers ¢rst meet the tissue vasculature
and angiogenic vasculature has properties di¡erent from those
of the preexisting systemic vasculature [4,5]. Speci¢c ligands
against molecules on the angiogenic endothelia are considered
to be useful for active targeting to tumor angiogenic vascula-
ture.
Recently, we prepared peptides speci¢c for tumor angiogen-
ic vasculature by using a phage-displayed peptide library for
delivering antiangiogenic agents or anticancer agents more
e¡ective to the angiogenic site, since such libraries are useful
for obtaining speci¢c peptides bound to appropriate target
molecules [6^8]. In brief, we injected a phage-displayed pep-
tide library into angiogenesis model mice. Phage clones that
accumulated in angiogenic blood vessels formed by the dorsal
air sac (DAS) method [9] were isolated. The advantage of this
method is that the selected phages have the ability to bind
only to angiogenic vessels, not to tumor cells. The peptide
sequences of the phage clones thus obtained were di¡erent
from any reported sequences obtained by in vivo biopanning
with tumor-bearing mice [10]. The obtained peptides, ASSSY-
PLIHWRPWAR, DRWRPALPVVLFPLH, and PRPGA-
PLAGSWPGTS, presented on selected phages actually accu-
mulated in the tumor tissues of two di¡erent tumor cell types
[10]. In the present study, we examined the e¡ect of these
isolated peptides on angiogenesis and observed that one of
these peptides, ASSSYPLIHWRPWAR, suppressed angiogen-
esis possibly through inhibition of endothelial cells migration.
Furthermore, the synthetic peptides based on the isolated
phages had the ability to suppress angiogenesis and tumor
growth.
2. Materials and methods
2.1. Tumor implantation
Highly metastatic murine B16BL6 melanoma cells were cultured in
Dulbecco’s modi¢ed Eagle’s medium/Ham’s F12 medium containing
10% fetal bovine serum (FBS, JRH Biosciences, Lenexa, KS, USA).
After harvesting of the cells, 1.0U106 cells were carefully injected
subcutaneously into the posterior £ank of 5-week-old C57BL/6 male
mice (Japan SLC Inc.). Meth A sarcoma cells were grown in 5-week-
old Balb/c male mice (Japan SLC Inc.) under an appropriate schedule,
and were similarly injected (1.0U106 cells/mouse) into the posterior
£ank of Balb/c mice. The animals were cared for according to the
animal facility guideline of the University of Shizuoka.
2.2. Inhibitory e¡ect of synthetic peptide against phage accumulation
Peptides were synthesized by use of Rink amide resin (0.4^0.7
mmol/g) and a peptide synthesizer ACT357 (Advanced ChemTech),
resulting in an amide at the carboxyl terminus. Preparation of M13
phages expressing unique amino acid sequence and in vivo phage
accumulation assay were done as described previously [10]. Puri¢ed
phage clone (5U108 cfu) and 0.25 Wmol of each synthetic peptide was
coinjected into tumor-bearing mice when the tumor size became about
10 mm in diameter. Four minutes after injection, the tumor tissue was
dissected, minced, and homogenized. The phages in homogenate were
recovered by infecting Escherichia coli K91KAN and titrated.
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2.3. Inhibitory e¡ect of synthetic peptide against migration of
human umbilical vein endothelial cells (HUVECs)
HUVECs (BioWhittaker, Walkersville, MD, USA) cultured in en-
dothelial cell basal medium (EBM, BioWhittaker) were labeled by an
incubation with 3P-O-acetyl-2P,7P-bis(carboxyethyl)-4 or 5-carboxy-
£uorescein, diacetoxy-methylester (BCECF-AM; Dojindo Laborato-
ries, Kumamoto, Japan) for determining the migration capacity by a
method as previously described [11]. After washing, 5U104 labeled
cells in EBM were introduced into a culture insert having a £uores-
cence blocking micropore membrane (FBM, Falcon HTS Fluoro-
Blok1 Inserts, Becton Dickinson) precoated with matrigel (Becton
Dickinson). Each culture insert was set into a well of a 24-well plate
containing 10% FBS^EBM. Then, an appropriate amount of rhVEGF
(Becton Dickinson) and synthetic peptides were added to the upper
side of the insert. After a 16-h incubation, the FBM was examined
under a £uorescence microscope for counting the number of cells
invaded.
2.4. Inhibitory e¡ect of dendoric synthetic peptide on in vivo
angiogenesis
Meth A sarcoma cells (1.0U107 cells/ring) were transferred into a
chamber ring of which both sides were covered with Millipore ¢lters
having a 0.45-Wm pore size (Millipore Co., Bedford, MA, USA). The
chamber rings were dorsally implanted into 5-week-old Balb/c male
mice. Dendoric synthetic 15-mer peptides (30 mg/kg/day) were in-
jected intravenously into a tail vein of the ring-bearing mice every
day starting at 1 day after ring implantation. Four days after the
implantation, the mice were sacri¢ced, and angiogenic vessels formed
at the dorsal skin were photographed.
2.5. Therapeutic experiment and statistical analysis
Synthetic 15-mer peptides and fragment peptides (20 mg/kg/day)
were injected subcutaneously into a site neighboring the tumor of
mice every day starting at 1 day after tumor implantation. Injection
sites of peptides were carefully selected to be at least 5 mm distant
from the tumor. The weight of each mouse, an indicator of side e¡ect,
and size of the tumor were monitored every day after initiation of
peptide administration. Tumor volume was calculated as described
previously [12]. Variance in a group was evaluated by the F-test, and
di¡erences in mean tumor volume were evaluated by Student’s t-test.
3. Results and discussion
Two distinct phage clones isolated with a homing capacity
to tumor new blood vessels presented ASSSYPLIHWRP-
WAR and DRWRPALPVVLFPLH sequences. Since both se-
quences have a common tripeptide sequence, WRP, this se-
quence may serve as an epitope responsible for the homing to
the angiogenic site. To con¢rm the capacity of the synthetic
peptides to accumulate in tumors and to examine the impor-
tance of WRP, we coinjected selected phage clones and cor-
responding synthetic peptides into B16BL6 melanoma-bearing
mice. As a result, all tested 8- and 5-mer fragment peptides
containing WRP sequence inhibited the accumulation of
phages expressing original 15-mer peptides (Fig. 1). These
inhibitory e¡ects indicate that these peptides may interact
with a speci¢c molecule(s) through a common sequence,
namely, WRP.
Next, we examined whether the angiogenic-speci¢c peptides
isolated from the phage-displayed library would have some
biological e¡ects on angiogenesis-related events or not. Since
solubility of ASSSYPLIHWRPWAR is superior to
DRWRPALPVVLFPLH, we used ASSSYPLIHWRPWAR
in the following study. At ¢rst, we examined the e¡ect of
the peptide on the invasion activity of endothelial cells that
had been activated by VEGF, since VEGF is known to acti-
vate motility and proliferation of endothelial cells. In fact,
VEGF activated invasion and proliferation of HUVECs in a
dose-dependent manner (data not shown). As shown in Fig.
2A, the ASSSYPLIHWRPWAR-peptide inhibited invasion of
VEGF-stimulated HUVECs in a dose-dependent manner, and
HUVEC migration declined to the background level in the
presence of 1 Wmol ASSSYPLIHWRPWAR-peptide. In con-
trast, treatment with the shu¥ed peptide of ASSSY-
PLIHWRPWAR, i.e. SAYPALSWSHRRIWP, which se-
quence had been determined by the randomization of the
parental peptide sequence, did not show any suppression of
HUVEC migration. The suppression of HUVEC invasion by
the treatment with ASSSYPLIHWRPWAR-peptide might not
be due to peptide-induced damage of HUVEC, since no cy-
totoxic action of the ASSSYPLIHWRPWAR-peptide against
HUVECs was observed at least up to a 100-Wmol concentra-
tion of the peptide (data not shown).
We next examined the inhibitory e¡ect of the peptides on
angiogenesis in vivo. Dendoric ASSSYPLIHWRPWAR,
(ASSSYPLIHWRPWAR)8K4K2K, but not dendoric shu¥ed
peptide, showed suppression of tumor angiogenesis in the
DAS model (Fig. 2B).
Since the peptides isolated from the phage library showed
speci¢c a⁄nity for tumor angiogenic sites, inhibited invasion
of HUVECs, and inhibited angiogenesis, these peptides are
expected to cause tumor dormancy via the suppression of
the angiogenic process. Therefore, we examined the e¡ect of
the peptides on tumor growth in vivo. Pentadecapeptides and
fragment peptides (20 mg/kg/day) were injected intravenously
into mice bearing Meth A sarcoma, and the tumor growth
inhibition by these peptides was investigated. As shown in
Fig. 3A, synthetic ASSSYPLIHWRPWAR peptide, but not
shu¥ed peptide SAYPALSWSHRRIWP, caused potent sup-
pression of tumor growth: tumor growth was inhibited 91.1%
determined at day 11, the ¢nal day of the treatment (signi¢-
cantly di¡erent from the control or shu¥ed peptide-treated,
P6 0.01). Similar results were obtained by the use of C-ter-
Fig. 1. Inhibitory e¡ect of WRP-containing fragment peptides
against a⁄nity-selected phage accumulation in tumor tissue. Phage
(5U108 cfu) and fragment peptides (0.25 Wmol) were intravenously
coinjected into tumor-bearing mice (n = 3). 4 min after the injection,
the deeply anesthetized mice were snap-frozen in liquid nitrogen,
and their tumor tissue was then dissected. The accumulated phages
at the tissue were recovered and titrated. Amino acid sequences of
injected peptides are indicated.
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minus octapeptide, IHWRPWAR (82.1% reduction, signi¢-
cantly di¡erent from the control or shu¥ed peptide-treated,
P6 0.01), and HWRPW pentapeptide (88.6% reduction, sig-
ni¢cantly di¡erent from the control or shu¥ed peptide-
treated, P6 0.01). N-terminus 8-mer ASSSYPLI, however,
did not show any suppression of tumor growth. Thus WRP-
containing sequences, at least HWRPW, may be important
for tumor growth suppression. After the last day of admin-
istration, tumor regrowth was observed (see after day 12
of Fig. 3A), suggesting that suppression of angiogenesis may
be cancelled. In other words, ASSSYPLIHWRPWAR and
the fragment peptides containing the WRP sequence
might cause tumor dormancy during treatment. The DRW-
RPALPVVLFPLH peptide also showed suppression of tumor
Fig. 2. Inhibition of HUVEC migration and in vivo angiogenesis by ASSSYPLIHWRPWAR peptide. A: BCECF-AM-labeled HUVECs were
added to matrigel-coated FluoroBlok inserts at a density of 50 000 cells/insert. The upper chamber was supplemented with 10 ng/ml rhVEGF
or without it. ASSSYPLIHWRPWAR peptide and shu¥ed peptide were added to the upper chamber at a concentration of 10 nM, 100 nM, or
1 Wmol, respectively, in the presence of rhVEGF. The migration was determined as described in Section 2. Signi¢cant di¡erences from rhVEGF
treated group without peptide are indicated (*P6 0.05, **P6 0.01, ***P6 0.001). B: Chamber rings containing Meth A sarcoma cells
(1.0U107 cells/ring, a, b, d) or medium alone (c) were dorsally implanted into 5-week-old Balb/c male mice. Dendoric synthetic 15-mer peptide,
ASSSYPLIHWRPWAR (a), dendoric shu¥ed peptide, SAYPALSWSHRRIWP (b), (30 mg/kg/day) or saline (c,d) was injected intravenously
via a tail vein of the ring-bearing mice every day starting at 1 day after the ring implantation. Four days after the implantation, the mice were
sacri¢ced, and angiogenic vessels formed in the dorsal skin were then examined.
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growth, but the activity of the peptides was slightly poorer
than that of ASSSYPLIHWRPWAR (data not shown).
To con¢rm the importance of the WRP sequence, we ex-
amined the tumor growth-suppressing activity by using ala-
nine-replaced pentapeptides, namely, HARPW, HWAPW,
and HWRAW. None of the three alanine-replaced peptides
of HWRPW suppressed the tumor growth (Fig. 3B), indicat-
ing that WRP is an essential sequence for the tumor growth
suppression. In fact, the WRP tripeptide also inhibited tumor
growth, although the e¡ect was less potent than that of
HWRPW (Fig. 3A,C). These results suggest that WRP is
the minimum and essential sequence for inducing tumor dor-
mancy, although the £anking sequence of WRP may also
important for modulating the activity. None of the peptides
tested showed any cytotoxic action in vitro against Meth A
sarcoma cells, nor caused body weight changes of animals in
vivo as an indicator of the side e¡ects (data not shown). In
these experiments, we started treatment of tumor-bearing mice
1 day after tumor implantation. We also examined the timing
of initiation of treatment by the use of ASSSYPLIHWRP-
WAR and fragment peptides (20 mg/kg/day), and observed
little suppression of tumor growth when the tumor sizes
were more than 4 mm in diameter at the initiation of treat-
ment (data not shown). These data may also support the idea
that the peptides a¡ect angiogenesis rather than the tumor
cells directly.
Angiogenesis is a critical event for tumor growth and meta-
stasis, and angiogenesis-suppressing agents may thus provide
a new modality of tumor treatment. In fact, angiostatin, endo-
statin [13], and the cleaved conformation of the serpin anti-
thrombin [14], which were discovered as endogenous angio-
genesis inhibitors, suppressed tumor growth. In the present
study, we identi¢ed a novel peptide having antiangiogenic
activity. The sequence of this peptide has not been isolated
in other tumor screenings. A homology search of ASSSY-
PLIHWRPWAR revealed that the HWRPW sequence in the
ASSSYPLIHWRPWAR peptide was identical to a part of the
sequence of Flt-4, which is a receptor for VEGFs. VEGF-C, a
subclass of VEGF that is reported to be an angiogenesis stim-
ulator [15], is known to bind to Flt-4 as well as to Flk-1/
KDR, another VEGF receptor. However, the importance of
the HWRPW sequence for the interaction of VEGF-C with its
receptors is not clear at present. Although the target mole-
cule(s) of the WRP-containing peptides is unclear at present,
angiogenic vasculature-speci¢c peptides, namely, WRP-related
peptides, shown here may be useful as a lead compound for
the development of new antiangiogenic agents. Moreover, the
peptides may also provide tools for active targeting of tumor
tissues: direct conjugation of the peptides with anticancer
agents or angiogenesis inhibitors, or modi¢cation of drug car-
riers with the peptides, may increase the local concentration of
agents in tumor angiogenic sites after administration.
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Fig. 3. Suppression of tumor growth in Meth A sarcoma-bearing
mice by treatment with synthetic peptides. 5-week-old Balb/c male
mice (n = 6) were implanted subcutaneously with Meth A sarcoma
into their left posterior £ank. At days 1^10 after tumor implanta-
tion, they were injected subcutaneously with various fragment pep-
tides (A,C) or alanine-substituted peptides (B) at a dose of 20 mg/
kg. Tumor volume was determined as described in Section 2. Stan-
dard deviation bars are shown only for the last points for the sake
of graphic clarity. Signi¢cant di¡erences from control are indicated
(*P6 0.05, **P6 0.01, ***P6 0.001).
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